Platelet Transfusion Therapy

被引：30

作者：

Thiagarajan, Perumal ^{[1
,2
]}

Afshar-Kharghan, Vahid ^{[3
]}

机构：

[1] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Pathol, Houston, TX 77030 USA

[2] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA

[3] MD Anderson Canc Ctr, Sect Benign Hematol, Houston, TX 77030 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2013年 / 27卷 / 03期

关键词：

Platelet transfusion; Alloimmunization; Transfusion triggers; Pathogen reduction; PATHOGEN INACTIVATION; CROSS-MATCH; APHERESIS PLATELETS; BLEEDING DIATHESIS; IN-VITRO; PHOSPHATIDYLSERINE; INCREMENTS; ALLOIMMUNIZATION; THROMBOCYTOPENIA; PERMEABILITY;

D O I：

10.1016/j.hoc.2013.03.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Platelet transfusion therapy has become an integral part of the treatment of patients with hematological and solid tumor malignancy receiving chemotherapy. Since its introduction almost 60 years ago, several advances and refinements have been introduced in the collection, storage, and administration to improve the safety and efficacy of platelet transfusion. This review summarizes the current practice and clinical approach to patients with thrombocytopenia. Existing evidence-based guidelines for appropriate platelet transfusion is reviewed.

引用

页码：629 / +

页数：16

共 50 条

[1] Platelet transfusion
Mo, Allison
Wood, Erica
Mcquilten, Zoe
CURRENT OPINION IN HEMATOLOGY, 2025, 32 (01) : 14 - 21
[2] Transfusion therapy with platelet concentrates
Isacchi, G
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1998, 21 : 98 - 102
[3] Platelet transfusion: Products, indications, dose, threshold and efficacy
Andreu, G.
Vasse, J.
Tardivel, R.
Semana, G.
TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2009, 16 (02) : 118 - 133
[4] Platelet transfusion: Alloimmunization and refractoriness
Prodger, Catherine F.
Rampotas, Alexandros
Estcourt, Lise J.
Stanworth, Simon J.
Murphy, Michael F.
SEMINARS IN HEMATOLOGY, 2020, 57 (02) : 92 - 99
[5] Platelet transfusion therapy
Goodnough, LT
JOURNAL OF CLINICAL APHERESIS, 2001, 16 (01) : 43 - 48
[6] CLINICAL ASPECTS OF PLATELET TRANSFUSION THERAPY
MURPHY, MF
INFUSIONSTHERAPIE UND TRANSFUSIONSMEDIZIN, 1994, 21 : 34 - 38
[7] Platelet transfusion practice and related transfusion reactions in a large teaching hospital
Liker, M.
Bojanic, I
Plenkovic, F.
Lukic, M.
Tomac, G.
Raos, M.
Cepulic, B. Golubic
TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2022, 29 (01) : 37 - 43
[8] Avatrombopag for the salvage treatment of platelet transfusion refractoriness
Qin, Yuehong
Wang, Yu
Zhang, Yujiao
Jiao, Yingying
Ye, Jieyu
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
[9] Platelet transfusion refractoriness
Hod, Eldad
Schwartz, Joseph
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (03) : 348 - 360
[10] Optimizing platelet transfusion therapy
Heal, JM
Blumberg, N
BLOOD REVIEWS, 2004, 18 (03) : 149 - 165

← 1 2 3 4 5 →